Ignite Creation Date:
2025-12-24 @ 3:45 PM
Ignite Modification Date:
2026-03-27 @ 3:50 AM
Study NCT ID:
NCT05197192
Status:
RECRUITING
Last Update Posted:
2025-08-17
First Post:
2021-09-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Sponsor:
German CLL Study Group
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CLL16
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |